Stifel Nicolaus analyst Derek Archila maintained a Hold rating on DBV Technologies SA – American (DBVT – Research Report) on January 4 and set a price target of $6.00. The company’s shares closed last Thursday at $6.48.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 13.5% and a 51.5% success rate. Archila covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Phasebio Pharmaceuticals, and Apellis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for DBV Technologies SA – American with a $10.67 average price target.
DBV Technologies SA – American’s market cap is currently $710.4M and has a P/E ratio of -3.10. The company has a Price to Book ratio of 2.46.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.